BIOMAT Database Logo BIOMAT Database Logo

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. 2007

Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W. Belvedere Ave., Baltimore, MD 21215, USA.

OBJECTIVE Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients. METHODS We examined the effect of aspirin (81, 162, and 325 mg/day for 4 weeks each) on platelet aspirin responsiveness in 120 stable outpatients (30 diabetic patients and 90 nondiabetic patients) with coronary artery disease (CAD) using light transmittance aggregometry (LTA), VerifyNow, platelet function analyzer (PFA)-100, and levels of urinary 11-dehydro-thromboxane B(2) (11-dh-TxB(2)). RESULTS In the total group, a low prevalence (0-2%) of aspirin resistance was observed with all aspirin doses as determined by arachidonic acid-induced LTA. Aspirin resistance was higher at the 81-mg dose in diabetic versus nondiabetic patients using collagen-induced LTA (27 vs. 4%, P = 0.001), VerifyNow (13 vs. 3%, P = 0.05), and urinary 11-dh-TxB(2) (37 vs. 17%, P = 0.03). Diabetic patients treated with 81 mg exhibited higher platelet function measured by VerifyNow, collagen- and ADP-induced LTA, and 11-dh-TxB(2) levels (P <or= 0.02 for all comparisons). Higher aspirin doses significantly inhibited platelet function and decreased aspirin resistance in diabetic patients (P < 0.05). CONCLUSIONS Diabetic patients with CAD treated with 81 mg aspirin exhibit a higher prevalence of aspirin resistance and have significantly higher ADP- and collagen-induced platelet aggregation, 11-dh-TxB(2) levels, and aspirin reaction units measured by VerifyNow than nondiabetic patients. Increased aspirin dosing resulted in similar rates of resistance and platelet function levels between groups. These findings indicate that diabetic patients exhibit a global high platelet reactivity phenotype that may be partially overcome by higher aspirin doses.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D003925 Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS. Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug

Related Publications

Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Comment on: DiChiara et al. (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study: Diabetes 56:3014-3019, 2007.
May 2008, Diabetes,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Letter by Klein regarding article, "Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study".
January 2008, Circulation,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data.
June 1998, Transplantation proceedings,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Platelet function in diabetic and nondiabetic patients with chronic obstructive pulmonary disease: a case control study.
January 2018, The clinical respiratory journal,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Effect of naftidrofuryl on platelet aggregation in plasma from aspirin treated patients: an in vitro study.
January 2000, Clinical hemorheology and microcirculation,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
[Platelet function, blood lipid, coagulation and fibrinolysis in diabetic and nondiabetic patients with arteriosclerosis].
January 1985, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
The effect of aspirin on the exercise-induced changes in platelet function and blood coagulation.
July 1974, Thrombosis research,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Effect of aspirin infusions on platelet function in humans.
July 1990, Clinical science (London, England : 1979),
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.
November 1999, Circulation,
Joseph DiChiara, and Kevin P Bliden, and Udaya S Tantry, and Miruais S Hamed, and Mark J Antonino, and Thomas A Suarez, and Oscar Bailon, and Anand Singla, and Paul A Gurbel
Effect of aspirin and aspirin lysinate on platelet function in smokers and non-smokers.
January 1980, Acta haematologica,
Copied contents to your clipboard!